University of Washington Arboviral Research Network (UWARN)

摘要：华盛顿大学虫媒病毒研究网络（UWARN） 华盛顿大学虫媒病毒研究网络（UWARN）将解决新出现和重新出现的 通过对虫媒病毒进行研究，包括目前高负担病原体， 登革热、基孔肯雅热和寨卡病毒。虫媒病毒还包括新出现和重新出现的病毒，如 马亚罗、乌纳、阿图什、日本脑炎、黄热病、克里米亚-刚果出血热和奥罗普什 病毒UWARN将利用UW Metacenter进行大流行病准备和强大的研究 实验室合作伙伴在巴西，塞内加尔，南非，巴基斯坦和台湾以及华盛顿大学部 全球卫生在能力建设方面的全球影响力。UWARN国际合作伙伴有 以机构和人口为基础的群组到位，以开展计划的研究和监测新的 病毒出现。拟议中的UWARN研究将创造新的人类病毒中和单克隆抗体， 抗体（Hu-nMabs），其可用作治疗剂或诊断剂。UWARN研究还将创造新的 诊断，由蛋白质设计研究所从头开始创建，作为人工蛋白质，当 体液中存在病毒抗体。最后，UWARN的研究将使人们了解如何 病毒操纵人类先天免疫系统，这些信息将用于设计生物标志物， 预测严重的疾病，并建议宿主导向的治疗，可能会导致更好的结果后， 虫媒病毒感染拟议的技术是通用的，可以迅速适应未来出现的任何技术。 虫媒病毒威胁UWARN的合作者涵盖病毒学、细菌学、真菌学和寄生虫感染， UWARN可以应对各种新出现的传染病威胁。UWARN国际实验室拥有 先进的功能，包括生物储存库与发电机电源备份-80 ℃冰柜，下一代 测序（NGS）能力，荧光细胞分选和BSL-3遏制设施。UWARN队列有 从患有急性发热性疾病的个体中采集的生物库样本，已知和未知虫媒病毒 疾病，伙伴关系网站已准备好进行人口和设施样本的前瞻性收集。 UWARN实验室将使用宏基因组NGS来检测附属队列中出现的新型病毒。UWARN伙伴 与昆虫学家和兽医合作，对节肢动物媒介和动物宿主进行采样， needed.其他创新能力包括巴西UWARN合作伙伴的带有NGS的移动的货车 能够在不到18小时的时间内进行实时、现场病毒测序和采样到病毒鉴定。第二 塞内加尔的合作伙伴IRESSEF计划建立一个类似的移动的车辆，用于病毒采样和测序， 塞内加尔和巴西集团将在技术转让和最佳做法方面与国际可持续能源系统论坛合作。UWARN 合作伙伴将作为其他新兴传染病研究中心的资源， 在单克隆抗体、蛋白质设计和宿主定向治疗方面的专业知识。

Abstract: University of Washington Arboviral Research Network (UWARN) The University of Washington Arboviral Research Network (UWARN) will address emerging and re-emerging infectious diseases by carrying out research on arboviruses that include current high burden pathogens including dengue, chikungunya, and Zika viruses. Arboviruses also include emerging and re-emerging viruses such as Mayaro, Una, Usutu, Japanese encephalitis, yellow fever, Crimean-Congo hemorrhagic fever, and Oropouche viruses. UWARN will leverage the UW Metacenter for Pandemic Disease Preparedness and strong research laboratory partners in Brazil, Senegal, South Africa, Pakistan and Taiwan as well as the UW Department of Global Health global reach in capacity building. The UWARN international Collaborating Partners have institution-based and population-based cohorts in place to carry out the planned research and monitor for new virus emergence. The proposed UWARN research will create new human viral-neutralizing monoclonal antibodies (Hu-nMabs) that can be used as therapeutics or diagnostics. UWARN research will also create new diagnostics, created ab initio by the Institute for Protein Design, as artificial proteins that release light when antibodies to virus are present in body fluids. Finally, UWARN research will generate an understanding of how viruses manipulate the human innate immune system, and this information will be used to design biomarkers to predict severe disease as well as to suggest host-directed therapies that could lead to better outcomes after arboviral infection. The proposed technologies are generic and could be rapidly adapted to any future emerging arbovirus threat. UWARN collaborators span virology, bacteriology, mycology, and parasitic infections, such that UWARN can respond to diverse emerging infectious diseases threats. UWARN international laboratories have advanced capabilities including biorepositories with generator-power backed-up -80C freezers, next-generation sequencing (NGS) capabilities, fluorescence cell sorting, and BSL-3 containment facilities. UWARN cohorts have biobanked samples taken from individuals during acute febrile illnesses, with known and unknown arboviral diseases, and partnership sites are poised for prospective collection of population and facility–based samples. UWARN labs will use metagenomic NGS to detect novel viral emergence in affiliated cohorts. UWARN Partners have collaborating entomologists and veterinarians to sample arthropod vectors and animal reservoirs as needed. Additional innovative capacity included the Brazil UWARN partner’s mobile van with on board NGS capability for real-time, on-site viral sequencing and sampling to viral identification in less than 18 hrs. A second partner, IRESSEF in Senegal, plans to set up a similar mobile vehicle for viral sampling and sequencing in Senegal and the Brazil group will collaborate with IRESSEF on technology transfer and best practices. UWARN partners will serve as a resource to other Emerging Infectious Diseases Research Centers (EIDRC) providing expertise in monoclonal antibodies, protein design, and host directed therapies.